Andrew Fromkin has served as a member of our board of directors since October 2019. Since January 2021, Mr. Fromkin has served as the Vant Portfolio Operating Partner for Roivant Sciences, Inc., or RSI. From January 2021 until April 2023, Mr. Fromkin served as the Acting Chief Executive Officer of Proteovant Sciences, Inc. From March 2015 to September 2020, Mr. Fromkin served as Chief Executive Officer of Tarveda Therapeutics, Inc. (formerly Blend Therapeutics, Inc.). From 2005 until 2011, Mr. Fromkin served in various roles for Clinical Data, Inc., including Executive Vice President (October 2005 until May 2006) and President, Chief Executive Officer and Director (May 2006 until May 2011). Prior to Clinical Data, Mr. Fromkin served as President and Chief Executive Officer of DoctorQuality, Inc., President, Chief Executive Officer and Director of Endo Surgical Devices, Inc. and Corporate Vice President, Business Development, for Merck-Medco, a wholly-owned subsidiary of Merck & Co. Mr. Fromkin began his career at Health Information Technologies, Inc. as General Manager of its subsidiary, MCA, and Director of Marketing and Payer Alliances for the parent company. From 2014 until 2016, Mr. Fromkin served on the board of Regado Biosciences, Inc. which became Tobira Therapeutics, Inc. in 2015. Mr. Fromkin received a B.A. from Brandeis University.
What is Andrew J. Fromkin's net worth?
The estimated net worth of Andrew J. Fromkin is at least $1.81 million as of March 7th, 2025. Fromkin owns 91,913 shares of Immunovant stock worth more than $1,809,767 as of March 21st. This net worth evaluation does not reflect any other assets that Fromkin may own. Learn More about Andrew J. Fromkin's net worth.
How do I contact Andrew J. Fromkin?
Has Andrew J. Fromkin been buying or selling shares of Immunovant?
During the past quarter, Andrew J. Fromkin has sold $156,800.00 in Immunovant stock. Most recently, Andrew J. Fromkin sold 8,000 shares of the business's stock in a transaction on Friday, March 7th. The shares were sold at an average price of $19.60, for a transaction totalling $156,800.00. Following the completion of the sale, the director now directly owns 91,913 shares of the company's stock, valued at $1,801,494.80. Learn More on Andrew J. Fromkin's trading history.
Who are Immunovant's active insiders?
Immunovant's insider roster includes Peter . (), Eva Barnett (CFO), Julia Butchko (Insider), Andrew Fromkin (Director), Michael Geffner (Chief Medical Officer), Douglas Hughes (Director), Mark Levine (Chief Legal Officer and Corporate Secretary), William Macias (Insider), George Migausky (Director), Atul Pande (Director), Peter Salzmann (CEO), Jay Stout (CTO), and Frank Torti (Director). Learn More on Immunovant's active insiders.
Are insiders buying or selling shares of Immunovant?
During the last twelve months, Immunovant insiders bought shares 1 times. They purchased a total of 16,845,010 shares worth more than $336,900,200.00. During the last twelve months, insiders at the sold shares 39 times. They sold a total of 244,592 shares worth more than $6,752,103.36. The most recent insider tranaction occured on March, 7th when Director Andrew J Fromkin sold 8,000 shares worth more than $156,800.00. Insiders at Immunovant own 5.9% of the company.
Learn More about insider trades at Immunovant. Information on this page was last updated on 3/7/2025.
